Friday Satellite Symposium on Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution, preceding the 63rd ASH Annual Meeting and Exposition.
- Improving Clinical Outcomes With Factor Replacement Therapy
An overview of factor replacement therapy including PK-driven therapy and a look at emerging agents in factor replacement
- Optimizing Nonfactor Therapy for Hemophilia A
Strategies for optimizing approved nonfactor therapies and an overview of new therapies currently in clinical trials
- Mitigating Complications and Overcoming Barriers in Patients Receiving Factor Replacement Therapy
Guidance on managing complications from factor therapy and addressing comorbidities in an aging patient population
- Question and Answer Session
- Key Takeaways
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Gulf States Hemophilia and Thrombophilia Center
Mark Reding, MD
Professor of Medicine
Division of Hematology, Oncology, and Transplantation
University of Minnesota
Guy A. Young, MD
Professor of Pediatrics
Director, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California
The goal of this activity is to improve the knowledge and competence of learners in using novel curative and noncurative therapeutic options for patients with hemophilia A.
This program is intended for physicians and other healthcare providers who care for patients with hemophilia A.
Upon completion of this activity, participants should be able to:
- Implement individualized hemophilia A prophylaxis strategies that optimize adherence, clinical outcomes, and utilization of resources
- Identify patients who are likely to benefit from nonfactor replacement therapy
- Mitigate complications and barriers to adherence in patients receiving factor replacement therapy
- Apply recent safety and efficacy data for both factor replacement and nonfactor prophylaxis in hemophilia A to clinical practice
- Manage comorbidities in patients receiving prophylaxis for hemophilia A
- Evaluate available data for novel agents and treatment strategies, and determine patients with hemophilia A who may be eligible for enrollment on a clinical trial
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.